Subcorneal pustular dermatosis (Sneddon-Wilkinson)L13.1

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 22.01.2024

Dieser Artikel auf Deutsch

Synonym(s)

Sneddon-Wilkinson disease; Sneddon-Wilkinson Syndrome; subcorneal pustular dermatosis; subcorneal pustulose; subcorneal pustulosis

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Sneddon and Wilkinson, 1956

DefinitionThis section has been translated automatically.

Rare, chronic, recurrent systemic disease with formation of strictly subcorneal, sterile pustules.

EtiopathogenesisThis section has been translated automatically.

The etiopathogenesis of this chronic pustulosis is unknown and its nosological classification remains controversial.

No evidence of pathogens in the pustules. The migration of neutrophils through the epidermis (subcorneal) indicates the presence of chemotactic factors in the upper epidermis. Tumor necrosis factor (TNF)-alpha, interleukin-8, C5a complement and IgA were detected in the subcorneal vesicles. An increase in interleukin-1beta was detected in the eruption phase of the pustule. IL-1beta is an activator of TNF-alpha, suggesting that it may play a role in the pathogenesis of the disease. The importance of TNF-alpha in the pathogenesis of the disease is emphasized by the response of the disease to TNF-alpha blockers such as adalimumab . Some authors suggest that neutrophil priming is a consequence of excessive production of TNF-alpha by keratinocytes. The serum level of the chemokine CCL17 (C-C motif chemokine ligand 17) is increased, which indicates a Th2 reaction (Bhargava S et al. 2020).

There are associations with autoimmunological connective tissue diseases, thyroid diseases, medications and infections. The disease has also been associated with pyoderma gangraenosum and chronic inflammatory bowel disease (i.e. Crohn's disease and ulcerative colitis). Associations with Sjögren's syndrome and systemic lupus erythematosus have also been reported.

Hematologic disorders: Numerous hematologic disorders, including aplastic anemia, lymphoma, chronic lymphocytic leukemia, IgG cryoglobulinemia, and monoclonal gammopathies, particularly IgA myeloma, have been associated with subcorneal pustulosis. These can occur years after onset. Regular screening (paraproteinemia) is also recommended for patients who initially test negative.

Malignancies: Malignancies of solid organs that have been reported include metastatic thymoma, apudoma and epidermoid carcinoma of the lung (Bhargava S et al. 2020).
Drugs: Drugs that can cause reactions with PS-like features have been reported. This concerns multikinase inhibitors sorafenib and gefitinib. Furthermore, paclitaxel, isoniazid, amoxicillin, cefazolin sodium and COVID-19 vaccination (McCoy T et al. 2023). The occurrence of subcorneal pustulosis due to dapsone and adalimumab has been reported as a therapeutic paradox.

Infections: Subcorneal pustulosis can be aggravated by various infections. Subcorneal pustulosis can be exacerbated by various infections (Mycoplasma pneumoniae infection, primary pulmonary coccidioidomycosis, urinary tract infections).

ManifestationThis section has been translated automatically.

Occurs more frequently from the age of 50.

Women are affected 4 times more frequently than men (?).

Less common in children.

LocalizationThis section has been translated automatically.

Mainly trunk and extremities, especially intertriginous areas are affected. The soles of the feet and palms, head and mucous membranes remain free.

Clinical featuresThis section has been translated automatically.

Symmetrically arranged, grouped, also anularly arranged, initially firm, as they grow larger, flaccid, "hypopyon-like" pustules, which are surrounded by a narrow inflammatory border. As the surface of the pustules is very easily damaged, they burst prematurely.

Confluence and transformation lead to the formation of circinate or polycyclic, weeping and crusty areas with collerette-like blister cover remnants.

The healing pattern with extensive erythema surrounded by a raised scaly ridge is also characteristic. The exanthema eruptions often have a craniocaudal course.

In fresh pustular eruptions, considerable feeling of illness, accompanied by a steep rise in temperature. Neutrophilic leukocytosis is always detectable.

LaboratoryThis section has been translated automatically.

Elevation of ESR and CRP.

Mostly pronounced neutrophilic leukocytosis.

Pustular smear: Numerous neutrophils, rarely eosinophils.

Serum protein electrophoresis: Paraproteinemia in up to 40% of cases. Frequent monoclonal IgA gammopathy or IgG gammopathy.

HistologyThis section has been translated automatically.

In clinically fully-developed pustular lesions there is a large, usually single-chambered, intraepithelial macropustule, the upper covering of which is formed in sections or exclusively by the stratum corneum (subcorneal pustule). The content of the pustule consists almost exclusively of neutrophilic granulocytes mixed with a few apoptotic keratinocytes. The epithelial pustular wall is only formed by a thin epidermal seam, which is spongiform and interspersed with neutrophil granulocytes. Dense inflammatory, predominantly neutrophilic infiltration of the underlying dermis.

Differential diagnosisThis section has been translated automatically.

Dermatitis herpetiformis: Immunohistologic differentiation possible by detection of granular IgA deposits in the papillary body.

Impetigo contagiosa: Bacteriologic examination

Bullous pemphigoid: Immunohistologic differentiation possible by detection of immunoglobulin deposits on the dermo-epidermal basement membrane.

Pemphigus vulgaris: Immunohistologic differentiation by detection of immunoglobulin deposits

Pemphigus foliaceus: (minus) variant of pemphigus vulgaris with high intraepidermal (subcorneal) continuity separation and thus very thin, volatile, easily tearing blister cover. In contrast to pemphigus vulgaris, mucosal changes are always absent in pemphigus foliaceus.

Pemphigus erythematosus: Detection of IgG antibodies in the intercellular substance and on the basement membrane, up to 60% positive lupus band test.

IgA pemphigus: IgA-AK against desmollin 1/2 and desmogleins: Positive immunofluorescence on the keratinocyte surface.

Genetic syndromes characterized by pustule formation, such as pyogenic arthritis/pyoderma gangrenosum/acne(PAPA syndrome) and SAPHO syndrome.

Pustular psoriasis: Some authors suggest that subcorneal pustulosis is closely related to pustular psoriasis. However, typical histopathologic features of pustular psoriasis, such as psoriasiform hyperplasia, parakeratosis and spongiform pustules, are not found in subcorneal pustulosis.

AGEP: Acute generalized exanthematous pustulosis: AGEP is a sudden, self-limited eruption typically triggered by a drug or infection. The presence of systemic symptoms, eosinophilia, marked edema of the papillary dermis, keratinocyte necrosis, mixed neutrophil-rich interstitial and mid-dermal infiltrates with eosinophils in the pustules or dermis distinguishes AGEP from Sneddon-Wilkinson type subcorneal pustulosis.

External therapyThis section has been translated automatically.

Drying measures with lotio alba and addition of 3-5% clioquinol R050, if necessary with glucocorticoids such as betamethasone emulsion/cream R030 or triamcinolone cream R259.

Radiation therapyThis section has been translated automatically.

Therapeutic successes with local PUVA therapy, also in combination with acitretin (RePUVA) are described.

Internal therapyThis section has been translated automatically.

DADPS (e.g. dapsone-fatol) 100-150 mg/day, although only a morbostatic effect can be achieved. Aromatic retinoids such as acitretin (Neotigason) 0.5-1.0 mg/kg bw/day or isotretinoin (e.g. Isotretinoin-ratiopharm; Aknenormin) 20-40 mg/day as a trial.

In treatment-resistant cases, methotrexate therapy(e.g. MTX) at 5-15 mg/week should be considered.

Alternatively, a trial with fumaric acid esters (Fumaderm) can be undertaken.

Alternative: In individual cases, the TNF-alpha inhibitors infliximab and etanercept have been successful.

Alternative: In further individual cases, successful treatment with Ciclosporin A, mycophenolate mofetil, adalimumab has been reported.

In patients with associated myeloma, the skin lesions healed after sufficient therapy of the myeloma.

Note(s)This section has been translated automatically.

The entity of this clinical picture is increasingly being questioned.

LiteratureThis section has been translated automatically.

  1. Bhargava S et al. (2020) Subcorneal pustular dermatosis: Comprehensive review and report of a case presenting during pregnancy. Int J Womens Dermatol 20:131-136
  2. Canpolat F et al. (2010) A case of subcorneal pustular dermatosis in association with monoclonal IgA gammopathy successfully treated with acitretin. J Dermatolog Treat 21:114-116
  3. Dallot A et al. (1988) Subcorneal pustular dermatosis (Sneddon-Wilkonson disease) with amicrobial lymph node suppuration and aseptic spleen abscesses. Brit J Dermatol 119: 803-807
  4. Ingber et al.(1983) Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after a diagnostic echogram. Report of two cases. J Am Acad Dermatol 9: 393-396
  5. Kerroum S et al. (2022) Maladie de Sneddon-Wilkinson: à propos d'un cas. Pan Afr Med J 43:115.
  6. Kocak M et al. (2003) Juvenile subcorneal pustular dermatosis: a case report. Pediatr Dermatol 20: 57-59
  7. Kreyberg I et al. (2023) Successful treatment of subcorneal pustular dermatosis targeting an underlying monoclonal IgA gammopathy. JAAD Case Rep 41:33-36.
  8. Kundak S et al. (2017) A child with subcorneal pustular dermatosis responded to IVIG treatment (Sneddon-Wilkinson disease). Reumatologia 55: 323-327.
  9. McCoy T et al. (2023) Sneddon-Wilkinson disease following COVID-19 vaccination. Dermatol Online J 29 doi: 10.5070/D329160218. P

  10. Nagai H, Harada S. (2002) Subcorneal pustular dermatosis accompanied by seronegative arthritis. Acta Derm Venereol 82: 318-319
  11. Naretto C et al. (2009) The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab. Lupus 18:856-857
  12. Rasch A et al. (2009) Subcorneal pustulosis with combined lack of IgG/IgM and monoclonal gammopathy type IgA/Kappa. J Dtsch Dermatol Ges 7:693-696
  13. Ratnarathorn M et al. (2008) Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. Dermatol Online J 15:6.
  14. Reed J, Wilkinson J (2000) Subcorneal pustular dermatosis. Clin Dermatol 18: 301-313
  15. Sandhu K et al (2003) Inverse subcorneal pustular dermatosis. J Eur Acad Dermatol Venereol 17: 348-349
  16. Scalvenzi M et al. (2013) Subcorneal pustular dermatosis in childhood: a case report and review of the literature. Case Rep Dermatol Med doi: 10.1155/2013/424797.
  17. Sneddon I, Wilkinson D (1956) Subcorneal pustular dermatosis. Br J Dermatol 68: 385-394
  18. Young PA et al (2021) Subcorneal pustular dermatosis associated with IgG monoclonal gammopathy of undetermined significance. Dermatol Online J 27:13030/qt71k801d3

Authors

Last updated on: 22.01.2024